journal article·2018-02-17Open access

Lipid nanoparticle-based co-delivery of epirubicin and BCL-2 siRNA for enhanced intracellular drug release and reversing multidrug resistance

Miao Yu, Shangcong Han, Zhongai Kou, Jialing Dai, Jiao Liu, Chen Wei, Yitong Li, Lutao Jiang, Yong Sun

Abstract

At present, combined therapy has become an effective strategy for the treatment of cancer. Co-delivery of the chemotherapeutic drugs and siRNA can more effectively inhibit tumor growth by nano drug delivery systems (NDDSs). Here, we prepared and evaluated a multifunctional envelope-type nano device (MEND). This MEND was a kind of composite lipid-nanoparticles possessing both the properties of liposomes and nanoparticles. In this study, an acid-cleavable ketal containing poly (β-amino ester) (KPAE) was used to bind siBCL-2 and the KPAE/siBCL-2 complexes were further coated by epirubicin (EPI) containing lipid to form EPI/siBCL-2 dual loaded lipid-nanoparticles. The results showed that the average size of EPI/siBCL-2-MEND was about 120 nm, and the average zeta potential was about 41 mV. The encapsulation efficiency (EE) of EPI and siBCL-2 was 86.13% and 97.07%, respectively. EPI/siBCL-2 dual loaded lipid-nanoparticles showed enhanced inhibition efficiency than individual EPI-loaded liposomes on HepG2 cells by MTT assay. Moreover, western blot experiment indicated co-delivery of EPI/siBCL-2 can significantly down-regulate the expression of P-glycoprotein (P-gp), while free EPI and EPI-loaded liposomes up-regulated it. Therefore, the strategy of co-delivering EPI and siBCL-2 simultaneously by lipid-nanoparticles showed promising potential in reversing multidrug resistance of tumor cells.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmacy, Qingdao University, Qingdao, China;

Department of Neurology, Shengli Hospital, Dongying, China

Funding

Shandong science and technology development projects · National Natural Science Fund Project in 2016

References (33)

Show source-provided references
1. 10.1016/j.ijpharm.2014.08.01910.1016/j.ijpharm.2014.08.019 ↗
2. 10.1021/nn103349h10.1021/nn103349h ↗
3. 10.1016/j.jconrel.2015.08.03210.1016/j.jconrel.2015.08.032 ↗
4. 10.1002/adhm.20150082610.1002/adhm.201500826 ↗
5. 10.1038/sj.cgt.770093110.1038/sj.cgt.7700931 ↗
6. 10.1038/nmat325310.1038/nmat3253 ↗
7. 10.1007/s10565-009-9141-y10.1007/s10565-009-9141-y ↗
8. Mastrobattista E · Nat Rev · 2006 · 5 · 115
9. 10.1016/j.jconrel.2007.06.01810.1016/j.jconrel.2007.06.018 ↗
10. 10.1016/j.addr.2007.10.00710.1016/j.addr.2007.10.007 ↗
11. 10.1021/bm801199z10.1021/bm801199z ↗
12. 10.1021/acs.nanolett.6b0291510.1021/acs.nanolett.6b02915 ↗
13. 10.1021/acsami.5b1178910.1021/acsami.5b11789 ↗
14. 10.1039/B914063H10.1039/B914063H ↗
15. 10.1021/bm100309y10.1021/bm100309y ↗
16. 10.1016/j.biomaterials.2008.02.01810.1016/j.biomaterials.2008.02.018 ↗
17. 10.1038/srep3522310.1038/srep35223 ↗
18. 10.1016/j.colsurfb.2016.06.03410.1016/j.colsurfb.2016.06.034 ↗
19. 10.3892/or.2016.463210.3892/or.2016.4632 ↗
20. 10.1186/2193-1801-2-63910.1186/2193-1801-2-639 ↗
21. 10.1038/sj.gt.330284310.1038/sj.gt.3302843 ↗
22. 10.18632/oncotarget.624310.18632/oncotarget.6243 ↗
23. 10.3892/ijo.2015.317410.3892/ijo.2015.3174 ↗
24. 10.1016/j.ijpharm.2013.06.02110.1016/j.ijpharm.2013.06.021 ↗
25. 10.1021/nn100968e10.1021/nn100968e ↗
26. 10.1016/j.ijpharm.2014.10.01410.1016/j.ijpharm.2014.10.014 ↗
27. 10.1016/j.jconrel.2014.10.00510.1016/j.jconrel.2014.10.005 ↗
28. 10.1016/j.biomaterials.2016.06.00710.1016/j.biomaterials.2016.06.007 ↗
29. 10.1016/j.jconrel.2016.02.02110.1016/j.jconrel.2016.02.021 ↗
30. Attia ABE · Small · 2014 · 10 · 428110.1002/smll.201401295 ↗
31. 10.1016/j.ijpharm.2015.10.02810.1016/j.ijpharm.2015.10.028 ↗
32. Gabizon A · Cancer Res · 1994 · 54 · 987
33. 10.1016/j.jconrel.2014.10.00110.1016/j.jconrel.2014.10.001 ↗